FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/789,536	ATTY. DOCKET NO.: C1039.70083US05
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 26. 2004	CONFIRMATION NO.: 9640
	APPLICANT: Arthur M. Krieg et al.	
	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minniefield
Sheet 1 of 2		

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
MM	B1	EPO	0 178 267 A2			04-16-1986	
MM	B2	JP	62-148428			07-02-1987	
MM	B3	PCT	US91/05815			08-14-1991	
MM	B4	PCT	US91/01327			09-05-1991	
MM	B5	PCT	0 216 133 B1			07-28-1993	
MM	B6	PCT	US94/02471			03-07-1994	
MM	B7	EP	0 302 758 B1			03-16-1994	
MM	B8	PCT	WO95/26204			10-1995	
MM	B9	PCT	WO96/02555			02-01-1996	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
MM	C1	Anfossi et al. (P.N.A.S., 86, 9, 3379-83, 89, HCAPLUS, AN 1989:475562)		
MM	C2	Azad, Raana F. et al., "Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region," *Antimicrobial Agents and Chemotherapy*, (1993) 37: 1945-1954.		
MM	C3	Azuma, I., "Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli," *Kekkaku* (1992) 67(9):45-55.		
MM	C4	Blaxter et al., "Genes expressed in Brugia malayi infective third stage larvae," Molecular and Biochemical Parasitology, (1996) 77:77-93.		
MM	C5	Etchart et al. "Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin" pp. 15775761 vol 72, 1998		
MM	C6	Etlinger, "Carrier Sequence Selection -- One Key to Successful Vaccines," *Immunology Today*, (1992) 13(2):52-55		
MM	C7	Fox, R.I., "Mechanism of Action of Hydroxychloroquine as an antirheumatic Drug," Chemical Abstracts (1994) 120:15, Abstract No. 182630		
MM	C8	Kataoka T, et al., "Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of *Mycobacterium bovis* BCG," *Jpn. J. Cancer Res* (1992) 83:244-247.		
MM	C9	Kimura Y, et al., "Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN," *J. Biochem* (1994) 116(5):991-994		
MM	C10	Kuramoto et al., "Oligonucleotide Sequences Required for Natural Killer Cell Activation," *Jpn. J. Cancer Res.*, (1992) 83:1128-1131.		

913559

NM Minnefield 9-19-05

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/789,536	ATTY. DOCKET NO.: C1039.70083US05
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 26, 2004	CONFIRMATION NO.: 9640
	APPLICANT: Arthur M. Krieg et al.	
Sheet 2 of 2	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
NM	C11	Messina et al., "The Influence of DNA Structure on the *in vitro* Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens," *Cellular Immunology* (1993) 147:148-157.		
NM	C12	Messina et al., "Stimulation of *in vitro* Murine Lymphocyte Proliferation by Bacterial DNA," *The Journal of Immunology* (1991) 147(6):1759-1764.		
NM	C13	Mottram, et al., "a Novel CDC2-Related Protein Kinase From Leishania Mexicana.LmmCRK1. Is Post-Translationally Regulated During the Life Cycle", *J. Biol. Chem.*, 268(28):21044-21052 (1993)		
NM	C14	Ren jun et al. (Zhonghua Zhong Zazhi, 1994, 16, 4, 247-50, HCAPLUS, AN 1995: 198874)		
NM	C15	Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," *Science* (1996) 273:352-354.		
NM	C16	Schnell et al., "Identification and Characterization of a Saccharomyces Cerevisiae Gene (PAR1) Conferring Resistance to Iron Chelators," *Eur. J. Biochem.* (1991) 200:487-493.		
NM	C17	Stull et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," *Pharmaceutical Research*, (1995) 12(4):465-483.		
NM	C18	Tanaka T. et al., "An Antisense Oligonucleotide Complementary to a Sequence in IG2b Germline Transcripts, Stimulates B Cell DNA Synthesis, and Inhibits Immunoglobulin Secretion, *J. Exp. Med.*, (1992) 175:597-607.		
NM	C19	Tokunaga T. et al., "Synthetic Oligonucleotides with Particular Base Sequences from the cDNA Encoding Proteins of *Mycobacterium bovis* BCG Induce Interferons and Activate Natural Killer Cells," *Microbiol. Immunol.* (1992) 36(1):55-66.		
NM	C20	Tokunaga, "A synthetic Single-stranded DNA, Poly(dG,dC), Induces Interferon-alpha/beta and -gamma, Augments Natural Killer Activity, and Suppresses Tumor Growth," *Jpn. J. Cancer Res.*(1988) 79(6):682-686.		
NM	C21	Wallace et al., "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries,," *Methods in Enzymology*, (1987) 152:432-442.		
NM	C22	Whalen R., "DNA Vaccines for Emerging Infectious Disease: What If?," *Emerging Infectious Disease*, (1996) 2(3):168-175.		
NM	C23	Wu G.Y. et al., "Receptor-mediated Gene Delivery and Expression *in vivo*," *J. Biological Chemistry*, (1988) 263:14621-14624.		
NM	C24	Yamamoto S. et al., "DNA from Bacteria, but not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth," *Microbiol. Immunol.* (1992) 36(9):983-997.		

EXAMINER	N M Minnifield	DATE CONSIDERED	9-19-05

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* copies of these patents and patent applications are not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.